Search research articles
Contact Us
Filters
Showing results (91-100 of 108) with videos related to
Page
of 11
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
September 12, 2001
Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts
J H Choi, H C Kim, H Y Lim, et al.
British Journal of Cancer
|
May 15, 2014
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
B Escudier, M D Michaelson, R J Motzer, et al.
Oncology Reports
|
July 31, 1998
Alpha-fetoprotein-producing gastric cancer
R Lee, S Y Rha, J B Ahn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 20, 2015
Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma
Y-K Kang, T Yau, J-W Park, et al.
Neoplasma
|
October 3, 2006
Concurrent chemoradiotherapy in patients with nasopharyngeal cancer: prognostic significance of low expression of bax
S Y Kang, Y T Oh, J H Han, et al.
Cancer Chemotherapy and Pharmacology
|
May 18, 2007
Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer
J Lee, Y H Im, S H Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 15, 2007
Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma
J Lee, T Lim, J E Uhm, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 29, 2016
Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition
S T Kim, S Y Kim, S J Klempner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2019
Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial
S T Kim, J H Kang, J Lee, et al.
British Journal of Cancer
|
October 28, 2015
A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer
S H Lim, T W Kim, Y S Hong, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 108) with videos related to
Sort By:
Page
of 11
Lung Cancer (Amsterdam, Netherlands)
|
September 12, 2001
Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leukocyte counts
J H Choi, H C Kim, H Y Lim, et al.
British Journal of Cancer
|
May 15, 2014
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
B Escudier, M D Michaelson, R J Motzer, et al.
Oncology Reports
|
July 31, 1998
Alpha-fetoprotein-producing gastric cancer
R Lee, S Y Rha, J B Ahn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 20, 2015
Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma
Y-K Kang, T Yau, J-W Park, et al.
Neoplasma
|
October 3, 2006
Concurrent chemoradiotherapy in patients with nasopharyngeal cancer: prognostic significance of low expression of bax
S Y Kang, Y T Oh, J H Han, et al.
Cancer Chemotherapy and Pharmacology
|
May 18, 2007
Evaluation of ER and Ki-67 proliferation index as prognostic factors for survival following neoadjuvant chemotherapy with doxorubicin/docetaxel for locally advanced breast cancer
J Lee, Y H Im, S H Lee, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 15, 2007
Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma
J Lee, T Lim, J E Uhm, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 29, 2016
Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition
S T Kim, S Y Kim, S J Klempner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 21, 2019
Capecitabine plus oxaliplatin versus gemcitabine plus oxaliplatin as first-line therapy for advanced biliary tract cancers: a multicenter, open-label, randomized, phase III, noninferiority trial
S T Kim, J H Kang, J Lee, et al.
British Journal of Cancer
|
October 28, 2015
A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI/FOLFIRI plus simvastatin for patients with metastatic colorectal cancer
S H Lim, T W Kim, Y S Hong, et al.
Page
of 11